Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples

Schmidt‐Erfurth, Ursula; Miller, John B.; Sickenberg, Michel; Bunse, A.; Laqua, H.; Gragoudas, E. S.; Zografos, Léonidas; Birngruber, Reginald; Bergh, Hubert van den; Strong, Andrew T.; Manjuris, U.; Fsadni, Mario G.; Lane, Anne Marie; Piguet, B; Bressler, Neil M.

doi:10.1007/s004170050092

Cited by 130 publications

(55 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the many controlled therapeutic trials over the last 25 years, [8][9][10][11][12][13][14][15][16][17][18][19][20] there is no treatment to date by which the impact of blindness from AMD in the community will be influenced. It is accepted that AMD represents a major and growing pubic health problem in Western Europe and North America for which no remedy exists.…”

mentioning

confidence: 99%

Towards an understanding of age-related macular disease

Bird

2003

Eye

View full text Add to dashboard Cite

mentioning

confidence: 99%

Towards an understanding of age-related macular disease

Bird

2003

Eye

View full text Add to dashboard Cite

“…It is cleared from most cells but preferentially remains with proliferative cells (such as new blood vessels). 63 A low-powered laser calibrated to a specific wavelength then activates the photosensitive drug to form peroxides. The result is cell death by apoptosis, mitochondrial or cell membrane destruction, vascular thrombosis or immune system destruction.…”

Section: Pdtmentioning

confidence: 99%

Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation

Meads

Salas

Roberts

et al. 2003

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAClinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation C Meads NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 01/25/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this ...

show abstract

“…Verteporfin has a short plasma half-life, which results in rapid clearance from the body [31]. Because the laser used to activate verteporfin is non-thermal, retinal function may be maintained in areas overlying the verteporfintreated choroidal neovascular lesions [32]. Verteporfin therapy is therefore suitable for the treatment of substantially more patients with subfoveal lesions than laser photocoagulation, and without immediate loss of vision [13,33].…”

Section: Treatment Options For Neovascular Amdmentioning

confidence: 99%

Common Eye Diseases of Elderly People: Identifying and Treating Causes of Vision Loss

Harvey

2002

Gerontology

View full text Add to dashboard Cite

Of the 38 million people who are blind, the majority, 22 million, are 60 years of age or older. The most common causes of vision loss in elderly people are age-related macular degeneration (AMD), cataract, glaucoma, and diabetic retinopathy. Of these, AMD is the leading cause of registered blindness in people over the age of 50 years in the western world. However, until recently, the treatment options for people with AMD have been severely limited. Verteporfin therapy is a new treatment that is efficacious and safe in selected patients with AMD who are at high risk of central vision loss. Physicians who are in regular contact with elderly people can help to minimize vision loss in this group of patients by being alert to the symptoms and signs of age-related eye diseases. This paper reviews each of the common eye diseases, with an emphasis on AMD because of the recent advances in treatment.

show abstract

Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples

Abstract: PDT allows temporary absence of leakage from CNV with preservation of visual acuity. The long-term prognosis of CNV secondary to age-related macular degeneration treated with repeated courses of PDT is being evaluated in a phase III trial.

Cited by 130 publications

References 18 publications

Towards an understanding of age-related macular disease

Towards an understanding of age-related macular disease

Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation

Common Eye Diseases of Elderly People: Identifying and Treating Causes of Vision Loss

Contact Info

Product

Resources

About